Pays: Irlande
Langue: anglais
Source: HPRA (Health Products Regulatory Authority)
DANTRON POLOXALCOL
Mundipharma Pharmaceuticals Limited
200mg/25mg
Oral Suspension
2011-01-07
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT CODALAX 200mg/25mg per 5ml suspension 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 5ml of suspension contains 200mg Poloxamer 188 and 25mg Dantron Excipients: Each 5ml also contains: 1000mg Sorbitol liquid (non-crystallising), 0.2ml 96% ethanol and 10mg Niasept sodium containing sodium ethyl, methyl and propyl parahydroxybenzoates (E215, E219 and E217). For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Oral suspension Orange-yellow coloured oral suspension, with an odour of peach and a sweet taste. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Use only in the treatment of analgesic induced constipation in the terminally ill patient. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Oral. Adults One or two 5 ml spoonfuls daily. Children Half to one 5 ml spoonfuls daily. 4.3 CONTRAINDICATIONS 1. In common with other gastro-intestinal evacuants, CODALAX and CODALAX Forte suspensions should not be given when acute or painful conditions of the abdomen are present or when the cause of constipation is suspected to be intestinal obstruction. 2. Pregnancy. 3. Hypersensitivity to any of the constituents of the product. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 07/01/2011_ _CRN 2093451_ _page number: 1_ 1. Oral administration of dantron has been reported to cause intestinal tumours in rats and mice. It has also been reported to be hepatocarcinogenic in rats as well as in mice. There is no sound evidence to conclude a no effect dose and therefore there may be a risk of such effects in humans. 2. In babies, children and patients wearing nappies, there may be staining of the Lire le document complet